Year: 2016
Type: review
Abstract: Tuberculosis (TB) remains the deadliest infectious disease. The widely used bacille Calmette-Guérin (BCG) vaccine offers only limited protection against TB. New vaccine candidates for TB include subunit vaccines and inactivated whole-cell vaccines, as well as live mycobacterial vaccines. Current developments in TB vaccines are summarized in this review.
Institutions: Max Planck Institute for Infection Biology, Dartmouth College
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,900
Awards: TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development, G2185367268, G2325242462, G434337789, Advanced Immunization Technologies, Max Planck Society for the Advancement of Science - to define a biosignature for increased risk of developing TB to: (i) accelerate clinical vaccine trials, (ii) facilitate design of preventive drug ..., G7246435601, G7655646194, Dartmouth/Boston University AITRP, G8188144576, G8562375244
OpenAlex ID: W2547186661